AKTOCYTE Tablets Developed for Radiotherapy Patients

In a significant collaborative effort, scientists from the Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd. Bengaluru have made strides in improving the quality of life for cancer patients undergoing radiotherapy.

Collaborative Effort

Experts from renowned institutions such as Bhabha Atomic Research Centre, Mumbai; Tata Memorial Hospital, Mumbai; and Advanced Centre for Training Research and Education in Cancer, Navi Mumbai, have teamed up with IDRS Labs. Their primary goal is to minimize the side effects associated with radiotherapy.

Remarkable Results in Pelvic Cancer Patients

The development of AKTOCYTE tablets has yielded remarkable results, especially for pelvic cancer patients experiencing radiotherapy-induced Cystitis (Blood in urine). Patients treated with AKTOCYTE tablets showcased extraordinary recovery, eliminating the need for surgical removal of the urinary bladder.

Versatility in Cancer Care

AKTOCYTE tablets are designed to serve multiple purposes in cancer care. Positioned as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, these tablets mark a significant advancement in cancer treatment.

FSSAI Approval

AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI), operating under the Ministry of Health & Family Welfare, Government of India. This regulatory clearance emphasizes the safety and compliance of AKTOCYTE tablets, providing assurance to both healthcare professionals and patients regarding its efficacy and quality.

Market Availability

Anticipated to hit the market in January 2024, AKTOCYTE tablets are poised to become a transformative addition to cancer treatment protocols. The collaboration between the institutions of DAE and industry has been instrumental in bringing this breakthrough to fruition. This development marks a pivotal moment in the convergence of scientific innovation and practical solutions for cancer care.

Month: Current Affairs - December, 2023

Category: Science & Technology Current Affairs